KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) FCF Margin (2017 - 2025)

Historic FCF Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 100.6%.

  • Aquestive Therapeutics' FCF Margin fell 122800.0% to 100.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 387.23%, marking a year-over-year increase of 4455900.0%. This contributed to the annual value of 3563.29% for FY2024, which is 35487100.0% down from last year.
  • Aquestive Therapeutics' FCF Margin amounted to 100.6% in Q3 2025, which was down 122800.0% from 80.19% recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' FCF Margin peaked at 79.16% during Q1 2023, and registered a low of 269.9% during Q1 2025.
  • Over the past 5 years, Aquestive Therapeutics' median FCF Margin value was 77.58% (recorded in 2021), while the average stood at 64.16%.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 19243000bps in 2021, then crashed by -1835000bps in 2025.
  • Over the past 5 years, Aquestive Therapeutics' FCF Margin (Quarter) stood at 77.58% in 2021, then surged by 201bps to 78.54% in 2022, then crashed by -148bps to 37.54% in 2023, then skyrocketed by 139bps to 14.55% in 2024, then plummeted by -791bps to 100.6% in 2025.
  • Its FCF Margin stands at 100.6% for Q3 2025, versus 80.19% for Q2 2025 and 269.9% for Q1 2025.